Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19273399 | 0.91 | ELANE (0.44) | ELANEPIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL1000476 | 0.83 | L3MBTL1 (0.52) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL19260899 | 0.80 | L3MBTL1 (0.45) | ELANEPIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL3222887 | 0.80 | L3MBTL1 (0.45) | ELANEPIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL1710746 | 0.79 | PIM1 (0.42) | ELANEPIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL31407376 | 0.79 | PIM1 (0.42) | ELANEPIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL1587770 | 0.79 | PIM1 (0.42) | ELANEPIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL29955151 | 0.78 | L3MBTL1 (0.44) | ELANEPIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL17883434 | 0.77 | ELANE (0.41) | ELANEPIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL30726141 | 0.77 | ELANE (0.41) | ELANEPIM1MARK3MAP4K2CAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017143134-A1 | FXR MODULATORS AND METHODS OF THEIR USE | ALIOS BIOPHARMA, INC. (US) | 2017-08-24 | — | — | WO | disclosed |